logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Says CHMP Recommends Approval Of Opdivo - Quick Facts

Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) announced Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four weeks (Q4W).

This is recommended for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

The CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response.

Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. Metastatic melanoma is the deadliest form of the disease and occurs when cancer spreads beyond the surface of the skin to other organs.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WeWork's parent company, We Company, said it has filed a lawsuit against Japanese conglomerate SoftBank Group Corp. for failing to consummate a $3 billion tender offer for the company's shares. After WeWork's failed attempt at an initial public offering last year, SoftBank acquired a majority stake in the office sharing company in a bailout, severing most ties with WeWork co-founder Adam Neumann. Walgreens is expanding drive-thru testing for the coronavirus to fifteen new locations in seven states across the U.S. later this week. They include Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. The drive-thru locations are part of Walgreens' collaboration with the administration, federal health agencies, and state and local authorities to expand access to COVID-19 testing. iPhone assembler Foxconn, otherwise known as Hon Hai Precision Industry Co. Ltd., is reportedly set to start manufacturing ventilators in the United States in partnership with medical device firm Medtronic plc., as the U.S. braces for the cornavirus (COVID-19) infection peak. Taiwan-based Foxconn will start manufacturing ventilators at its Wisconsin factory within the next four to six weeks.
Follow RTT
>